Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Follow-Up Questions
What is the price performance of BBLG stock?
The current price of BBLG is $2.13, it has decreased 0.46% in the last trading day.
What are the primary business themes or industries for Bone Biologics Corp?
Bone Biologics Corp belongs to Biotechnology industry and the sector is Health Care
What is Bone Biologics Corp market cap?
Bone Biologics Corp's current market cap is $3.8M
Is Bone Biologics Corp a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Bone Biologics Corp, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
